Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Royalty Pharma stock | $37.5

Learn how to easily invest in Royalty Pharma stock.

Royalty Pharma plc

Royalty Pharma plc is a biotechnology business based in the US. Royalty Pharma shares (RPRX) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Royalty Pharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RPRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Royalty Pharma stock price (NASDAQ: RPRX)

Use our graph to track the performance of RPRX stocks over time.

Royalty Pharma shares at a glance

Information last updated 2021-10-18.
Latest market close$37.50
52-week range$34.25 - $52.59
50-day moving average $37.36
200-day moving average $40.32
Wall St. target price$51.43
PE ratio 31.085
Dividend yield $0.64 (1.73%)
Earnings per share (TTM) $1.24

Buy Royalty Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Royalty Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Royalty Pharma price performance over time

Historical closes compared with the close of $37.5 from 2021-10-22

1 week (2021-10-15) -2.32%
1 month (2021-09-24) 1.08%
3 months (2021-07-23) -7.02%
6 months (2021-04-23) -14.01%
1 year (2020-10-23) -3.87%
2 years (2019-10-20) N/A
3 years (2018-10-20) N/A
5 years (2016-10-20) N/A

Is Royalty Pharma under- or over-valued?

Valuing Royalty Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Royalty Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Royalty Pharma's P/E ratio

Royalty Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Royalty Pharma shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Royalty Pharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Royalty Pharma's EBITDA

Royalty Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.9 billion.

The EBITDA is a measure of a Royalty Pharma's overall financial performance and is widely used to measure a its profitability.

To put Royalty Pharma's EBITDA into context you can compare it against that of similar companies.

Royalty Pharma financials

Revenue TTM $2.2 billion
Operating margin TTM 83.27%
Gross profit TTM $1.9 billion
Return on assets TTM 7.24%
Return on equity TTM 19.76%
Profit margin 43.4%
Book value $13.43
Market capitalisation $23.3 billion

TTM: trailing 12 months

Shorting Royalty Pharma shares

There are currently 8.4 million Royalty Pharma shares held short by investors – that's known as Royalty Pharma's "short interest". This figure is 40.4% up from 6.0 million last month.

There are a few different ways that this level of interest in shorting Royalty Pharma shares can be evaluated.

Royalty Pharma's "short interest ratio" (SIR)

Royalty Pharma's "short interest ratio" (SIR) is the quantity of Royalty Pharma shares currently shorted divided by the average quantity of Royalty Pharma shares traded daily (recently around 3.1 million). Royalty Pharma's SIR currently stands at 2.7. In other words for every 100,000 Royalty Pharma shares traded daily on the market, roughly 2700 shares are currently held short.

To gain some more context, you can compare Royalty Pharma's short interest ratio against those of similar companies.

However Royalty Pharma's short interest can also be evaluated against the total number of Royalty Pharma shares, or, against the total number of tradable Royalty Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Royalty Pharma's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Royalty Pharma shares in existence, roughly 20 shares are currently held short) or 0.0252% of the tradable shares (for every 100,000 tradable Royalty Pharma shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Royalty Pharma.

Find out more about how you can short Royalty Pharma stock.

Royalty Pharma share dividends


Dividend payout ratio: 24.21% of net profits

Recently Royalty Pharma has paid out, on average, around 24.21% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.77% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Royalty Pharma shareholders could enjoy a 1.77% return on their shares, in the form of dividend payments. In Royalty Pharma's case, that would currently equate to about $0.64 per share.

While Royalty Pharma's payout ratio might seem low, this can signify that Royalty Pharma is investing more in its future growth.

Royalty Pharma's most recent dividend payout was on 14 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 18 August 2021 (the "ex-dividend date").

Royalty Pharma's dividend payout ratio is perhaps best considered in relation to those of similar companies.

Royalty Pharma overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 45 marketed therapies and 9 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. .

Frequently asked questions

What percentage of Royalty Pharma is owned by insiders or institutions?
Currently 16.415% of Royalty Pharma shares are held by insiders and 63.014% by institutions.
When does the fiscal year end for Royalty Pharma?
Royalty Pharma's fiscal year ends in December.
Where is Royalty Pharma based?
Royalty Pharma's address is: 110 East 59th Street, New York, NY, United States, 10022
What is Royalty Pharma's ISIN number?
Royalty Pharma's international securities identification number is: GB00BMVP7Y09
What is Royalty Pharma's CUSIP number?
Royalty Pharma's Committee on Uniform Securities Identification Procedures number is: 76028H100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site